Amylin Pharmaceuticals Appoints Marcea Bland Lloyd Senior Vice President and General Counsel
February 06 2007 - 4:05PM
PR Newswire (US)
Lloyd to Establish Corporate Affairs Organization SAN DIEGO, Feb. 6
/PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc.
(NASDAQ:AMLN) today announced that Marcea Bland Lloyd has been
appointed Senior Vice President, Legal and Corporate Affairs, and
General Counsel. Ms. Lloyd comes to Amylin from VHA, Inc., most
recently serving as Group Senior Vice President, Chief
Administrative Officer, General Counsel and Secretary, where she
provided strategic and operational leadership to their legal, human
resources, government affairs, facilities, corporate
communications, risk management and community relations functions.
She previously spent over 20 years with Medtronic, Inc. Ms. Lloyd
will have responsibility for all legal affairs of the company and
will establish a Corporate Affairs department, bringing Amylin's
Government Affairs, Public Policy, Corporate Communications and
Community Relations functions together into one organization. "We
are delighted to attract a leader of Marcea's stature, insight and
background to Amylin," said Ginger L. Graham, CEO of Amylin
Pharmaceuticals. "Her broad experience in legal, public policy,
corporate development and administration brings further dimension
and depth to our executive leadership team. Marcea will work with
our senior leaders to shape policies that enable Amylin to achieve
its long-term business objectives, consistent with the best
interests of our patients, customers, employees and communities
where we live and work." Additionally, the Company is creating a
new corporate officer position: Vice President, Governance and
Compliance, and Corporate Secretary. Lloyd A. Rowland has been
named to this new role and will oversee the company's efforts in
corporate governance and compliance and serve as counsel to the
Board of Directors. Ms. Lloyd is Chair of the Executive Leadership
Foundation and an associate of the Women Business Leaders of the US
Health Care Industry Foundation. She earned her J.D. degree from
Northwestern University and holds a B.S./B.A. from Knox College in
Galesburg, Illinois. About Amylin Pharmaceuticals Amylin
Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and
commercialization of innovative medicines. Amylin has developed and
gained approval for two first-in-class medicines for diabetes,
SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide)
injection. Amylin's research and development activities leverage
the company's expertise in metabolism to develop potential
therapies to treat diabetes and obesity. Amylin is located in San
Diego, California with over 1500 employees nationwide. Further
information on Amylin Pharmaceuticals is available at
http://www.amylin.com/. DATASOURCE: Amylin Pharmaceuticals, Inc.
CONTACT: Alice Bahner, Executive Director, Investor Relations of
Amylin Pharmaceuticals, Inc., +1-858-552-2200 Web site:
http://www.amylin.com/
Copyright
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Jul 2023 to Jul 2024